



ESMO 2018 INDUSTRY SATELLITE SYMPOSIUM

Is earlier better? Translating clinical evidence into individualised treatment decisions in advanced prostate cancer

SUNDAY 21 OCTOBER 2018
13:00-14:30

HALL A1 - ROOM 16 | MESSE MUNICH | MUNICH, GERMANY

SCIENTIFIC COMMITTEE

Eleni Efstathiou, USA
Boris Hadaschik, Germany

FACULTY

Simon Chowdhury, UK
Noel Clarke, UK
Karim Fizazi, France
Eric Small, USA

LEARNING OBJECTIVES

After this satellite symposium, participants should be able to:

- Discuss the need for, and the clinical benefits of, earlier treatment in patients with advanced prostate cancer
- Compare different treatment options for individual patients based on clinical evidence.

TIME	SESSION	FACULTY
13:00-13:15	The evolving landscape in advanced prostate cancer: current open questions	Boris Hadaschik, Germany
13:15-13:45	Individualising treatments in mHSPC: an option or a must?	Karim Fizazi, France, and Noel Clarke, UK
13:45-14:15	nmCRPC: is treatment really needed?	Eric Small, USA, and Simon Chowdhury, UK
14:15-14:30	A look to the future of prostate cancer treatment	Eleni Efstathiou, USA

With the support of Janssen Pharmaceutical Companies of Johnson & Johnson in EMEA
Janssen Pharmaceutica NV
Turnhoutseweg 30
B-2340 Beerse, Belgium

Date of preparation: July 2018
PHEM/ONCS/0618/0002e